---
layout: default
title: Ceftiofur
parent: 僅模型預測 (L5)
nav_order: 99
evidence_level: L5
indication_count: 10
---

# Ceftiofur
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Ceftiofur: From Veterinary Bacterial Infections to Interventricular Septum Aneurysm

---

## One-Sentence Summary

Ceftiofur is a third-generation cephalosporin antibiotic approved exclusively for **veterinary use** — it has no approved human indications and is not marketed in Denmark.
The TxGNN model predicts it may be relevant for **Interventricular Septum Aneurysm**, with a high model confidence score of 96.01%.
However, there are currently **0 clinical trials** and **0 publications** supporting this direction, and the mechanistic rationale is considered weak — this prediction is likely a false positive signal arising from indirect knowledge graph pathways.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Veterinary use only — bacterial infections in livestock (no approved human indication) |
| Predicted New Indication | Interventricular Septum Aneurysm |
| TxGNN Prediction Score | 96.01% |
| Evidence Level | L5 (model prediction only — no supporting studies) |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the evidence pack. Based on known pharmacological class information, Ceftiofur is a third-generation beta-lactam cephalosporin antibiotic developed exclusively for veterinary medicine. It acts by binding to penicillin-binding proteins (PBPs) and inhibiting bacterial cell wall peptidoglycan synthesis, thereby exerting a bactericidal effect. It is routinely used in cattle, swine, and poultry for respiratory tract infections and other bacterial diseases.

Interventricular septum aneurysm is a structural cardiac defect — either congenital or acquired as a sequela of infection (e.g., post-endocarditis tissue thinning). In the latter scenario, there is an indirect theoretical connection to antibiotic therapy during the acute infectious phase. However, Ceftiofur itself has no known mechanism for repairing or modifying cardiac structures, and standard treatment for infective endocarditis employs human-approved agents such as Penicillin G, Ampicillin, or Vancomycin.

The high TxGNN score most likely reflects an indirect graph path in the knowledge graph — specifically a "bacterial infection → cardiac pathology" linkage — rather than a genuine Ceftiofur-specific therapeutic signal. The complete absence of human pharmacokinetic, dosing, and safety data for this veterinary compound further undermines the plausibility of this prediction. This is considered a likely false positive.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Denmark Market Information

Ceftiofur holds no marketing authorisations in Denmark and is not registered with the Danish Medicines Agency (Lægemiddelstyrelsen). It is a veterinary medicinal product with no approved human indications in any jurisdiction.

---

## Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.

> **Important note**: Ceftiofur is a veterinary-only compound. Human pharmacokinetic data, human dosing recommendations, human toxicity profiles, and clinical drug interaction data are entirely absent. Any consideration of human use would require de novo clinical development, including first-in-human studies.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
All five unique predicted indications (interventricular septum aneurysm, pulmonary valve disease, orofacial clefting syndrome, Laubry-Pezzi syndrome, and genetic syndromic Pierre Robin syndrome) are structural or congenital conditions for which an antibiotic agent has no plausible direct therapeutic mechanism. The evidence level is L5 across the board, and Ceftiofur has no approved human use in any country. The TxGNN predictions in this case are assessed as knowledge graph noise amplification arising from sparse disease nodes and indirect infection-related pathways.

**To proceed, the following would be needed — at minimum:**

- Confirmation that Ceftiofur is not a veterinary-exclusive compound (i.e., identification of any investigational human use context)
- Basic human pharmacokinetic and toxicology data (Phase 0 / first-in-human studies)
- A credible mechanistic hypothesis linking beta-lactam antibiotic activity to the predicted structural cardiac or craniofacial conditions
- Regulatory consultation with the Danish Medicines Agency (Lægemiddelstyrelsen) and EMA on the pathway for repurposing a veterinary compound for human use
- Review of whether TxGNN graph topology in the region of these disease nodes is adequately dense to support reliable predictions

> ⚠️ **Research disclaimer**: This report is for research reference only and does not constitute medical advice. Drug repurposing candidates require clinical validation before any application in patient care.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

